{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:12:40Z","timestamp":1791065560293,"version":"4.1.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,7]]},"abstract":"<jats:p>We propose hidradenitis suppurativa (HS) is added to the list of weight-related comorbidities in the new National Institute for Health and Care Excellence guideline on obesity. Effective obesity management in patients with HS could help reduce disease severity, pain and cardiovascular risk, and improve quality of life and the efficacy of biologic therapy. In addition, it could reduce the costs of HS-associated care (GP visits, hospital outpatient attendances, biologic drugs, inpatient admissions, elective and emergency surgery).<\/jats:p>","DOI":"10.1093\/ced\/llad109","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T08:28:50Z","timestamp":1679905730000},"page":"802-803","source":"Crossref","is-referenced-by-count":5,"title":["Hidradenitis suppurativa should be recognized as a weight-related comorbidity in National Institute for Health and Care guidelines on managing obesity"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-7718","authenticated-orcid":false,"given":"Khawar","family":"Hussain","sequence":"first","affiliation":[{"name":"Department of Dermatology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Khalil","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-6056","authenticated-orcid":false,"given":"Neil P","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"2023101015313104600_llad109-B1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis","volume":"157","author":"Jfri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2023101015313104600_llad109-B2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjd.14024","article-title":"Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies","volume":"173","author":"Tzellos","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023101015313104600_llad109-B3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jaad.2019.08.034","article-title":"Association between obesity and hidradenitis suppurativa among children and adolescents: a population-based analysis in the United States","volume":"82","author":"Balgobind","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023101015313104600_llad109-B4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1203475419874412","article-title":"Weight loss and dietary interventions for hidradenitis suppurativa: a systematic review","volume":"24","author":"Sivanand","year":"2020","journal-title":"J\u00a0Cutan Med Surg"},{"key":"2023101015313104600_llad109-B5","article-title":"Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa","author":"Nosrati","year":"2022","journal-title":"Int J Dermatol"},{"key":"2023101015313104600_llad109-B6","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"2023101015313104600_llad109-B7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.15233","article-title":"The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide","volume":"177","author":"Jennings","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023101015313104600_llad109-B8","author":"National Institute for Health and Care Excellence (NICE)"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad109\/50189320\/llad109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/7\/802\/51989371\/llad109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/7\/802\/51989371\/llad109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:32:04Z","timestamp":1696951924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/7\/802\/7086610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":8,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,3,27]]},"published-print":{"date-parts":[[2023,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad109","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2023,3,27]]}}}